This content is machine translated Obesity therapy Why lifestyle modification alone is not effective According to current understanding, obesity is considered a multifactorial chronic disease. The overriding goals of treatment are to improve the general state of health and weight-associated diseases or risk factors.…
View Post 5 min This content is machine translated Obesity The pounds tumble under incretin-based therapies Antiadiposita can effectively support the success of lifestyle interventions and thus close a treatment gap. In Switzerland, the GLP-1 RAs liraglutide and semaglutide are currently the most effective in the…
View Post 5 min This content is machine translated Obesity GLP-1-based drugs close the treatment gap The WHO has declared obesity to be a global health problem and weight reduction is an important measure in the prevention and treatment of metabolic diseases such as type 2…
View Post 6 min This content is machine translated Incretin-based therapies for type 2 diabetes Evolution of therapy options continues Incretin mimetics are an attractive treatment option, particularly for the subgroup of overweight type 2 diabetics, as they not only have glucose-lowering effects, but have also demonstrated clinical benefits in…
View Post 3 min This content is machine translated GLP-1-RA and dual GLP-1/GIP agonists. Tackling obesity – not only diabetics benefit from the effects While glucagon-like peptide (GLP)-1 receptor agonists have been successfully used in the treatment of diabetes for some time, there are now agents that activate not only the GLP-1 receptor but…
View Post 3 min This content is machine translated GLP-1-RA in type 2 diabetes Broad spectrum of action – weight reduction is also supported GLP-1 receptor agonists promote insulin secretion from pancreatic beta cells, leading to decreased glucose release by the liver and increasing insulin sensitivity. Moreover, they slow down gastric emptying and thus…
View Post 4 min This content is machine translated SUSTAIN-10: Post-hoc analysis Semaglutide and liraglutide in type 2 diabetes: effective and safe with and without SGLT-2-i Based on empirical evidence, professional societies recommend early combination of metformin with an SGLT-2 inhibitor or a GLP-1 receptor agonist in type 2 diabetics. Increasingly, a combined application of the…
